Larissa M. Matukas

Larissa M. Matukas

Auto-generated profile, based on publicly available information

Larissa M. Matukas

Division of Infectious Diseases, Department of Medicine, St. Michael's Hospital, Toronto, ON, Canada; Division of Microbiology, Department of Laboratory Medicine, St. Michael's Hospital, Toronto, ON, Canada

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2011 in Journal of Cystic Fibrosis
Verified
Journal Article
Open access
PDF file
VWValerie Waters
Valerie Waters
EAEshetu G. Atenafu
Eshetu G. Atenafu
JSJuliana Giraldo Salazar
Juliana Giraldo Salazar
ALAnnie Lu
Annie Lu
YYYvonne Yau
Yvonne Yau
FRFelix Ratjen
Felix Ratjen
Chronic Stenotrophomonas maltophilia infection in cystic fibrosis (CF) patients has recently been shown to be an independent risk factor for pulmonary exacerbation [ 1 x [1] Waters, V., Yau, Y., Prasad, S., Lu, A., Atenafu, E., Crandall, I. et al. Stenotrophomonas maltophilia in cystic fibrosis: serologic response and effect on lung disease. Am J Respir Crit Care Med. 2011; 183: 635–640 Crossref | PubMed | Scopus (88) | Google Scholar See all References ] [1] . Antibiotic use, however, is a known risk factor for the isolation of S. maltophilia in the respiratory tract of CF patients and increased treatment of pulmonary exacerbations may simply be selecting out S. maltophilia in the airways of sicker CF patients [ 2 x [2] Marchac, V., Equi, A., Le Bihan-Benjamin, C., Hodson, M., and Bush, A. Case–control study of Stenotrophomonas maltophilia acquisition in cystic fibrosis patients. Eur Respir J. 2004; 23: 98–102 Crossref | PubMed | Scopus (43) | Google Scholar See all References , 3 x [3] Talmaciu, I., Varlotta, L., Mortensen, J., and Schidlow, D.V. Risk factors for emergence of Stenotrophomonas maltophilia in cystic fibrosis. Pediatr Pulmonol. 2000; 30: 10–15 Crossref | PubMed | Scopus (66) | Google Scholar See all References , 4 x [4] Graff, G.R. and Burns, J.L. Factors affecting the incidence of Stenotrophomonas maltophilia isolation in cystic fibrosis. Chest. 2002; 121: 1754–1760 Crossref | PubMed | Scopus (58) | Google Scholar See all References , 5 x [5] Denton, M., Todd, N.J., Kerr, K.G., Hawkey, P.M., and Littlewood, J.M. Molecular epidemiology of Stenotrophomonas maltophilia isolated from clinical specimens from patients with cystic fibrosis and associated environmental samples. J Clin Microbiol. 1998; 36: 1953–1958 PubMed | Google Scholar See all References ]. The consequences of the increased number of pulmonary exacerbations in CF patients with chronic S. maltophilia infection are unknown.

29 October 2015 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
LTLinda R. Taggart
Linda R. Taggart
ELElizabeth Leung
Elizabeth Leung
MMMatthew P. Muller
Matthew P. Muller
LMLarissa M. Matukas
Larissa M. Matukas
NDNick Daneman
Nick Daneman
Antimicrobial decision making in intensive care units (ICUs) is challenging. Unnecessary antimicrobials contribute to the development of resistant pathogens, Clostridium difficile infection and drug related adverse events. However, inadequate antimicrobial therapy is associated with mortality in critically ill patients. Antimicrobial stewardship programs are increasingly being implemented to improve antimicrobial prescribing, but the optimal approach in the ICU setting is unknown. We assessed the impact of an audit and feedback antimicrobial stewardship intervention on antimicrobial use, antimicrobial costs, clinical outcomes and microbiologic outcomes in two ICUs with different patient populations. The audit and feedback intervention was implemented in a trauma and neurosurgery ICU (TNICU) and a medical surgical ICU (MSICU) at a 465-bed teaching hospital in Toronto, Canada. ICU patients were reviewed Monday to Friday by a physician and pharmacist with infectious diseases training. Recommendations related to appropriate antimicrobial use were presented to ICU teams during a dedicated daily meeting. A controlled interrupted time series analysis was used to compare outcomes in the 12 months before and after the intervention. Cardiovascular and coronary care ICUs served as control units. Mean total monthly antimicrobial use in defined daily doses (DDD) per 1000 patient days was reduced 28 % in the TNICU (1433 vs. 1037) but increased 14 % in the MSICU (1705 vs. 1936). In the time series analysis, total monthly antimicrobial use in the TNICU decreased by 375 DDD per 1000 patient days (p < 0.0009) immediately following the intervention, followed by a non-significant downward trend in use of −9 DDD per 1000 patient days (p = 0.56). No significant changes in antimicrobial use were identified in the MSICU. Antimicrobial use temporarily increased in one control unit and remained unchanged in the other. There were no changes in mortality, length of stay, readmission rate, incidence of C. difficile infection or resistance patterns of E. coli and P. aeruginosa in either intervention unit. Audit and feedback antimicrobial stewardship programs can lead to significant reductions in total antimicrobial use in the ICU setting. However, this effect may be context-dependent and further work is needed to determine the ingredients necessary for success.

1 March 2015 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
YYYvonne C.W. Yau
Yvonne C.W. Yau
FRFelix Ratjen
Felix Ratjen
ETElizabeth Tullis
Elizabeth Tullis
PWPearce Wilcox
Pearce Wilcox
AFAndreas Freitag
Andreas Freitag
VWValerie Waters
Valerie Waters

1 November 2018 in Diagnostic Microbiology and Infectious Disease
Verified
Journal Article
Closed access
ACAaron Campigotto
Aaron Campigotto
LGLee Goneau
Lee Goneau
LMLarissa M. Matukas
Larissa M. Matukas

1 April 2016 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
PDF file
ACAaron Campigotto
Aaron Campigotto
MMMatthew P. Muller
Matthew P. Muller
LTLinda R. Taggart
Linda R. Taggart
RHReem Haj
Reem Haj
ELElizabeth Leung
Elizabeth Leung
LMLarissa M. Matukas
Larissa M. Matukas
Cumulative susceptibility test data (CSTD) are used to guide empirical antimicrobial therapy and to track trends in antibiotic resistance. The Clinical and Laboratory Standards Institute recommends reporting CSTD at least annually and sets the minimum number of isolates per reported organism at 30. To comply, many hospitals combine data from multiple intensive care units (ICUs); however, this may not be appropriate to guide empirical therapy because of variations in patient populations. In this study, susceptibility data for two different ICUs at a tertiary care hospital in Toronto, Canada, were used to create a traditional CSTD report, which combined data from different ICUs, and a rolling-average CSTD report, which pooled 2 years of data for each ICU separately. For simplicity, data for only the most common Gram-negative organisms ( Escherichia coli , Pseudomonas aeruginosa ) and the most relevant antibiotics (ciprofloxacin, piperacillin-tazobactam) were examined. With the rolling-average method, significant differences in susceptibility were seen between the ICUs in 50% of the organism-antimicrobial combinations. Furthermore, the 3% median year-over-year difference in susceptibilities seen for the 16 organism-antibiotic combinations by using the traditional method was lower than the 14% median difference seen for the 20 between-ICU within-year comparisons obtained using the rolling-average method. Changes in our selection of empirical antibiotics resulted from this revised approach, and our results suggest that pooling data from ICUs with different patient populations may not be appropriate. A rolling-average method may be an appropriate strategy for the creation of individual-unit CSTD reports.